ReviewFrontiers in medicine2019
HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents.
Review in Frontiers in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Renal function trajectories in hepatitis C infection: differences between renal healthy and chronic kidney disease individuals.Scientific reports · 2021Trial
- Alpha-1-microglobulin as an early biomarker in renal extrahepatic manifestations of hepatitis C virus infection.World journal of nephrology · 2026Article
- Minimal change disease in treatment-naïve hepatitis C virus infection: A case report and literature review.Clinical nephrology. Case studies · 2025Article
- Renal Manifestations of Chronic Hepatitis C: A Review.Journal of clinical medicine · 2024Review
- An Aggressive Case of Cryoglobulinemia and Membranoproliferative Glomerulonephritis: A Case Report.Cureus · 2024Article
- Article
- Autoimmunity and Infection in Glomerular Disease.Microorganisms · 2023Review
- Prevalence and risk factors for chronic kidney disease in Indonesia: An analysis of the National Basic Health Survey 2018.Journal of global health · 2022Article
- From Bench to Bedside: Clinical and Biomedical Investigations on Hepatitis C Virus (HCV) Genotypes and Risk Factors for Albuminuria.Bioengineering (Basel, Switzerland) · 2022Article
- Review
- Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.World journal of hepatology · 2022Review
- Serum cystatin C is an early renal dysfunction biomarker in patients with hepatitis C virus.Egyptian liver journal · 2022Article
- Inflammation and kidney involvement in human viral diseases caused by SARS-CoV-2, HIV, HCV and HBV.The journal of venomous animals and toxins including tropical diseases · 2021Review
- Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence.Pathogens (Basel, Switzerland) · 2019Review
- Kidney Histopathology of Patients with Hepatitis C Infection and Diabetes Mellitus before and after Availability of Direct-Acting Antiviral Therapy.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection is a systemic disorder that frequently associates with extrahepatic manifestations, including nephropathies. Cryoglobulinemia is a typical extrahepatic manifestation of HCV infection that often involves kidneys with a histological pattern of membranoproliferative glomerulonephritis. Other, less common renal diseases related to HCV infection include membranous nephropathy, focal segmental glomerulosclerosis, IgA nephropathy, fibrillary and immunotactoid glomerulopathy. Over the last decades, the advent of direct-acting antiviral therapies has revolutionized treatment of HCV infection, dramatically increasing the rates of viral clearance. In patients where antiviral therapy alone fails to induce renal disease remission add-on B-cell depleting agents represent an alternative to counteract the synthesis of pathogenic antibodies. Immunosuppressive therapies, such as steroids, alkylating agents, and plasma exchanges, may still represent an effective option to inhibit immune-complex driven inflammatory response, but the potentially associated increase of HCV replication and worsening of liver disease represent a serious limitation to their use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.